Renaissance Technologies's CTNM Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 57,100 shares of Contineum Therapeutics, Inc. (CTNM) worth $652,653, representing 0.00% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 3 quarters.
Based on 13F filings, Renaissance Technologies has maintained this position in CTNM for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 26,796 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Contineum Therapeutics (CTNM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Contineum Therapeutics (CTNM) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +15,900 | Add 38.59% | 57,100 | $11.43 |
| Q3 2025 | +26,796 | Add 186.03% | 41,200 | $11.75 |
| Q2 2025 | +14,404 | New Buy | 14,404 | $3.97 |
Renaissance Technologies's Contineum Therapeutics Investment FAQs
Renaissance Technologies first purchased Contineum Therapeutics, Inc. (CTNM) in Q2 2025, acquiring 14,404 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Contineum Therapeutics, Inc. (CTNM) for 3 quarters since Q2 2025.
Renaissance Technologies's largest addition to Contineum Therapeutics, Inc. (CTNM) was in Q3 2025, adding 41,200 shares worth $484,100.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 57,100 shares of Contineum Therapeutics, Inc. (CTNM), valued at approximately $652,653.
As of the Q4 2025 filing, Contineum Therapeutics, Inc. (CTNM) represents approximately 0.00% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Contineum Therapeutics, Inc. (CTNM) was 57,100 shares, as reported at the end of Q4 2025.